Free Trial
→ How to play the Biggest IPO in stock market history! (From InvestPub) (Ad)tc pixel Free BIO.B Stock Alerts

Bio-Rad Laboratories (BIO.B) Competitors

Bio-Rad Laboratories logo
$304.15 0.00 (0.00%)
As of 06/15/2026
Compare

BIO.B vs. VLTO, FTV, NVMI, RVTY, and CAMT

Should you buy Bio-Rad Laboratories stock or one of its competitors? MarketBeat compares Bio-Rad Laboratories with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Rad Laboratories include Veralto (VLTO), Fortive (FTV), Nova (NVMI), Revvity (RVTY), and Camtek (CAMT). These companies are all part of the "measuring and control equipment" industry.

How does Bio-Rad Laboratories compare to Veralto?

Bio-Rad Laboratories (NYSE:BIO.B) and Veralto (NYSE:VLTO) are both measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 91.3% of Veralto shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.4% of Veralto shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Veralto has a net margin of 17.33% compared to Bio-Rad Laboratories' net margin of 6.52%. Veralto's return on equity of 34.63% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Veralto 17.33%34.63%13.44%

Veralto has a consensus target price of $105.88, indicating a potential upside of 26.62%. Given Veralto's stronger consensus rating and higher possible upside, analysts plainly believe Veralto is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Veralto
0 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.45

Bio-Rad Laboratories has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Veralto has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Veralto has higher revenue and earnings than Bio-Rad Laboratories. Veralto is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.59B3.14$759.90M$6.0750.11
Veralto$5.50B3.73$940M$3.8721.61

In the previous week, Veralto had 3 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 3 mentions for Veralto and 0 mentions for Bio-Rad Laboratories. Veralto's average media sentiment score of 0.41 beat Bio-Rad Laboratories' score of 0.00 indicating that Veralto is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Veralto Neutral

Summary

Veralto beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Fortive?

Fortive (NYSE:FTV) and Bio-Rad Laboratories (NYSE:BIO.B) are both measuring and control equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

94.9% of Fortive shares are held by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are held by institutional investors. 0.7% of Fortive shares are held by insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fortive has a net margin of 12.84% compared to Bio-Rad Laboratories' net margin of 6.52%. Fortive's return on equity of 12.66% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Fortive12.84% 12.66% 6.98%
Bio-Rad Laboratories 6.52%3.56%2.49%

Fortive currently has a consensus target price of $61.62, indicating a potential upside of 0.70%. Given Fortive's stronger consensus rating and higher probable upside, equities analysts plainly believe Fortive is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortive
2 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.07
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Fortive had 7 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 7 mentions for Fortive and 0 mentions for Bio-Rad Laboratories. Fortive's average media sentiment score of 1.28 beat Bio-Rad Laboratories' score of 0.00 indicating that Fortive is being referred to more favorably in the media.

Company Overall Sentiment
Fortive Positive
Bio-Rad Laboratories Neutral

Fortive has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Bio-Rad Laboratories has lower revenue, but higher earnings than Fortive. Fortive is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortive$4.16B4.48$579.20M$1.6736.64
Bio-Rad Laboratories$2.59B3.14$759.90M$6.0750.11

Summary

Fortive beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Nova?

Bio-Rad Laboratories (NYSE:BIO.B) and Nova (NASDAQ:NVMI) are both measuring and control equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Bio-Rad Laboratories has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Nova has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Nova has a net margin of 29.21% compared to Bio-Rad Laboratories' net margin of 6.52%. Nova's return on equity of 21.77% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Nova 29.21%21.77%12.56%

Nova has a consensus price target of $518.22, indicating a potential downside of 9.81%. Given Nova's stronger consensus rating and higher possible upside, analysts plainly believe Nova is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Nova
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.82

In the previous week, Nova had 12 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 12 mentions for Nova and 0 mentions for Bio-Rad Laboratories. Nova's average media sentiment score of 1.44 beat Bio-Rad Laboratories' score of 0.00 indicating that Nova is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Nova Positive

Bio-Rad Laboratories has higher revenue and earnings than Nova. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Nova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.59B3.14$759.90M$6.0750.11
Nova$880.58M20.74$259.22M$8.0271.65

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 83.0% of Nova shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 1.0% of Nova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Nova beats Bio-Rad Laboratories on 13 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Revvity?

Bio-Rad Laboratories (NYSE:BIO.B) and Revvity (NYSE:RVTY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Bio-Rad Laboratories has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Revvity has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Bio-Rad Laboratories has higher earnings, but lower revenue than Revvity. Revvity is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.59B3.14$759.90M$6.0750.11
Revvity$2.86B3.97$241.20M$2.0948.69

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Revvity has a net margin of 8.26% compared to Bio-Rad Laboratories' net margin of 6.52%. Revvity's return on equity of 8.00% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Revvity 8.26%8.00%4.83%

Revvity has a consensus target price of $107.73, suggesting a potential upside of 5.86%. Given Revvity's stronger consensus rating and higher possible upside, analysts plainly believe Revvity is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Revvity
1 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.21

In the previous week, Revvity had 2 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 2 mentions for Revvity and 0 mentions for Bio-Rad Laboratories. Revvity's average media sentiment score of 0.71 beat Bio-Rad Laboratories' score of 0.00 indicating that Revvity is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Revvity Positive

Summary

Revvity beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Camtek?

Bio-Rad Laboratories (NYSE:BIO.B) and Camtek (NASDAQ:CAMT) are both mid-cap measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Camtek has a consensus target price of $174.33, indicating a potential downside of 5.73%. Given Camtek's stronger consensus rating and higher possible upside, analysts clearly believe Camtek is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Camtek
0 Sell rating(s)
7 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

Bio-Rad Laboratories has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Camtek has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

Bio-Rad Laboratories has higher revenue and earnings than Camtek. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Camtek, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.59B3.14$759.90M$6.0750.11
Camtek$496.07M17.09$50.72M$0.87212.56

Camtek has a net margin of 9.63% compared to Bio-Rad Laboratories' net margin of 6.52%. Camtek's return on equity of 22.26% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Camtek 9.63%22.26%11.70%

In the previous week, Camtek had 3 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 3 mentions for Camtek and 0 mentions for Bio-Rad Laboratories. Camtek's average media sentiment score of 0.72 beat Bio-Rad Laboratories' score of 0.00 indicating that Camtek is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Camtek Positive

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 41.9% of Camtek shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 79.4% of Camtek shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Camtek beats Bio-Rad Laboratories on 13 of the 16 factors compared between the two stocks.

Get Bio-Rad Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIO.B vs. The Competition

Export
MetricBio-Rad LaboratoriesMED IndustryMedical SectorNYSE Exchange
Market Cap$8.14B$3.38B$6.48B$23.46B
Dividend YieldN/A2.25%2.66%4.05%
P/E Ratio50.1119.6923.9631.48
Price / Sales3.14307.44518.3420.71
Price / Cash30.3553.6127.4818.64
Price / Book1.108.0510.544.71
Net Income$759.90M$23.89M$3.56B$1.07B
7 Day PerformanceN/A0.75%0.12%1.37%
1 Month Performance16.58%-0.61%1.44%3.42%
1 Year Performance36.30%43.43%24.05%23.09%

Bio-Rad Laboratories Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIO.B
Bio-Rad Laboratories
N/A$304.15
flat		N/A+21.6%$8.14B$2.59B50.118,200
VLTO
Veralto
4.5207 of 5 stars		$82.88
+0.3%		$105.88
+27.7%		-15.0%$20.36B$5.59B21.4217,000
FTV
Fortive
3.4996 of 5 stars		$59.82
-0.4%		$61.62
+3.0%		-13.1%$18.24B$4.24B35.8210,000
NVMI
Nova
2.8736 of 5 stars		$559.62
+10.1%		$518.22
-7.4%		+172.6%$17.79B$902.53M69.781,612
RVTY
Revvity
2.9792 of 5 stars		$101.46
+0.2%		$107.73
+6.2%		+7.6%$11.32B$2.86B48.5411,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:BIO.B) was last updated on 6/16/2026 by MarketBeat.com Staff.
From Our Partners
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
"You'll own nothing and be happy" (it's not a theory anymore)
Since 1913, the evidence is clear… Once they force everyone onto CBDCs, there will be no escape. Every tran...
Decentralized Masters | Sponsoredtc pixel
This Could Be the Biggest Monetary Shift in 50 Years
Tucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold ...
Americas Gold Company | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Nuclear Is Back. The Next Market May Be Uranium.
Nuclear is moving back to the center of America's power strategy. AI data centers need reliable electricity, a...
i2i Marketing Group, LLC | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel